A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of ...

Last week, Merck and Ridgeback Biotherapeutics announced Phase 3 results of molnupiravir, an oral antiviral drug, in patients with mild-to-moderate Covid-19. In a trial that included more than 750 ...

In the fall of 2015, Dr. Mark Denison was preparing for a long drive home from Alabama after making a presentation at a scientific meeting when a colleague asked him to stick around for lunch and ...

Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...

Regulators in the U.K. became the first public health body to approve the use of experimental COVID antiviral drug molnupiravir on Thursday. The U.K.'s Medicines and Healthcare Products Regulatory ...

In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...

Patients and their doctors have voted with their scripts. Overwhelmingly, they are choosing Pfizer's Paxlovid and rejecting Merck's molnupiravir. So much so that when Paxlovid is unavailable (which is ...

An experimental drug prevented half of severe coronavirus infections that would otherwise have sent people to the hospital, according to a study released Friday, offering promise that COVID-19 could ...

Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the ...

The antiviral agent incorporates RNA-like building blocks into the genome of the virus. The United States recently secured 1.7 million doses of a compound that could help to treat Covid-19 patients.

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...